Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
The Opti-HER HEART trial aimed to optimize activity while minimizing cardiac risk by combining trastuzumab, pertuzumab, and paclitaxel with non-pegylated liposomal doxorubicin in the treatment of HER2-positive...
Source: BMC Medicine - Category: Internal Medicine Authors: Joaqu Ãn Gavilá, Mafalda Oliveira, Tomás Pascual, Jose Perez-Garcia, Xavier Gonzà lez, Jordi Canes, Laia Paré, Isabel Calvo, Eva Ciruelos, Montserrat Muñoz, Juan A. Virizuela, Isabel Ruiz, Raquel Andrés, Antonia Perelló, Jerónimo MartÃnez, Serafà Tags: Research article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Heart | HER2 | Herceptin | Internal Medicine | Neoadjuvant Therapy